Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment

作者：Shu Su, Fungjun Chen, Xin Lv, Qi Liang, Zhou Ding, Wei Ren, Ming Wei, Ye Liu, Lixia Yu, Baorui Liu, Lifeng Wang · 发表于：Cancer Immunology Immunotherapy · 年份：2024 · DOI：10.1007/s00262-023-03620-2 · 被引用次数：10 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies、Lung Cancer Treatments and Mutations

Abstract Background The introduction of the anti-PD-1 antibody has greatly improved the clinical outcomes of patients with non-small cell lung cancer (NSCLC). In this study, we retrospectively analyzed the efficacy of PD-1 antibody-based therapy in patients with locally advanced inoperable or metastatic NSCLC and reported an association between peripheral blood biomarkers and clinical response in these patients. Methods This single-center study included medical record data of patients with NSCLC treated with the PD-1 antibody as a first-line or subsequent line of treatment, either as monotherapy or in combination with chemotherapy. The patients were enrolled from 2020 to 2022. We dynamically evaluated multiple Th1 and Th2 cytokines in the blood serum and analyzed the phenotype of T cells from the peripheral blood to explore the correlation between cytokine levels, T cell phenotypes, and clinical response. Results A total of 88 patients with stage IIIA-IV NSCLC were enrolled, out of which 60 (68.18%) achieved a partial response (PR), 13 (14.77%) had stable disease (SD), and 15 (17.05%) experienced disease progression (PD). The disease control rate was 82.95%. Our results suggested a significant reduction ( P = 0.002, P < 0.005) in lymphocyte absolute counts after treatment in patients with PD. Higher levels of IFN- γ ( P = 0.023, P < 0.05), TNF- α ( P = 0.00098, P < 0.005), IL-4 ( P = 0.0031, P < 0.005), IL-5 ( P = 0.0015, P < 0.005), and IL-10 ( P = 0.036, P &l...